Purchase Order 36C26126P0387

The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 21, awarded Edwards Lifesciences LLC a $65,000 firm fixed-price purchase order on January 29, 2026, for transcatheter aortic valve replacement (TAVR) surgical implants restocking. The contract, with performance completion by April 28, 2026, supports the VA Palo Alto Health Care System's cardiac surgical program by replenishing inventory of specialized cardiovascular devices. This award carries no set-aside designation and represents a single-source procurement reflecting Edwards Lifesciences' exclusive manufacturing capability for these advanced medical technologies. The purchase order operates under Edwards Lifesciences' broader five-year indefinite delivery contract with VISN 21, valued at $6.5 million through December 31, 2030, which establishes a consignment model allowing the health system to maintain optimal inventory levels of Edwards Lifesciences' cardiac devices for on-demand procurement during surgical procedures.

Edwards Lifesciences LLC, a for-profit limited liability company and subsidiary of Edwards Lifesciences Corporation, specializes in the design, manufacture, and distribution of advanced cardiovascular medical devices including transcatheter heart valves, surgical implants, and annuloplasty systems. As a self-certified small disadvantaged business, the company has become a critical supplier to the VA healthcare system, having received over 200 prime federal contract awards since 2025 across multiple VISNs and the Defense Health Agency. The company's primary product lines supplied through these contracts include TAVR systems, SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valves with RESILIA tissue technology, INSPIRIS RESILIA aortic valves, and PASCAL mitral valve repair systems, supporting the VA's mission to deliver specialized cardiac care to the veteran population.